w 12 has been researched along with Psoriasis Arthropathica in 1 studies
W 12: calmodulin antagonist; W13 analog with Cl deleted from benzene ring
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pinter, A | 1 |
| Puig, L | 1 |
| Schäkel, K | 1 |
| Reich, A | 1 |
| Zaheri, S | 1 |
| Costanzo, A | 1 |
| Tsai, TF | 1 |
| Smith, SD | 1 |
| Lynde, C | 1 |
| Brnabic, A | 1 |
| Reed, C | 1 |
| Hill, J | 1 |
| Schuster, C | 1 |
| Riedl, E | 1 |
| Paul, C | 1 |
1 other study available for w 12 and Psoriasis Arthropathica
| Article | Year |
|---|---|
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).
Topics: Adult; Arthritis, Psoriatic; Biological Products; Humans; Psoriasis; Severity of Illness Index; Sulf | 2022 |